-
Sector Analysis
NewIndonesia Cards and Payments – Opportunities and Risks to 2028
GlobalData’s ‘Indonesia Cards and Payments: Opportunities and Risks to 2028' report provides detailed analysis of market trends in the Indonesian cards and payments industry. It provides values and volumes for a number of key performance indicators in the industry, including cash, credit transfers, mobile wallets, cards, cheques, and direct debits during the review-period (2020–24e). The report also analyzes various payment card markets operating in the industry and provides detailed information on the number of cards in circulation, transaction values and...
-
Company Insights
NewFitbit Inc Pipeline Insight and Competitive Landscape, 2024
Empower your strategies with our Fitbit Inc Pipeline Insight and Competitive Landscape, 2024 report and make more profitable business decisions. Fitbit Inc (Fitbit), a subsidiary of Google LLC, is a supplier of health and fitness solutions. The company involved in the production of connected fitness devices. Its products portfolio includes Fitbit Sence, Fitbit Versa 3, Fitbit Versa 2, Fitbit Luke, Gorjana, Fitbit Inspire 2, Fitbit Charge 4 Special Edition, And Fitbit Charge 4. Fitbit is involved in providing the software...
-
Analyst Opinions
Oil and Gas Sector Strategies in Electric Vehicles
Oil and Gas Sector Strategies in EV Report Overview As the world races to meet net zero targets, both public and private sectors are having to find alternative solutions and invest in innovative technologies. The transportation sector accounts for a significant portion of the global energy use, leading to a hunt for alternative fuel solutions for sustainable mobility. A type of alternative fuel vehicle that has been growing rapidly is battery electric vehicles (BEVs), also referred to as EVs. The...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RNS-60 in Acute Ischemic Stroke
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RNS-60 in Acute Ischemic Stroke report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RNS-60 in Acute Ischemic Stroke Drug Details: RNS-60 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anbenitamab in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anbenitamab in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anbenitamab in Gastric Cancer Drug Details: KN-026 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anbenitamab in Gastroesophageal (GE) Junction Carcinomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anbenitamab in Gastroesophageal (GE) Junction Carcinomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anbenitamab in Gastroesophageal (GE) Junction Carcinomas Drug Details: KN-026...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BP-1002 in Cutaneous T-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BP-1002 in Cutaneous T-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BP-1002 in Cutaneous T-Cell Lymphoma Drug Details: BP-1002 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Erfonrilimab in Metastatic Hepatocellular Carcinoma (HCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Erfonrilimab in Metastatic Hepatocellular Carcinoma (HCC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Erfonrilimab in Metastatic Hepatocellular Carcinoma (HCC) Drug Details: KN-046...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Erfonrilimab in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Erfonrilimab in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Erfonrilimab in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: KN-046...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Erfonrilimab in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Erfonrilimab in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Erfonrilimab in Colorectal Cancer Drug Details: KN-046 is under development for...